Intrexon Corp (NYSE:XON) CEO Randal J. Kirk bought 1,000,000 shares of the business’s stock in a transaction dated Friday, January 19th. The shares were bought at an average cost of $12.50 per share, for a total transaction of $12,500,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Intrexon Corp (NYSE:XON) traded up $0.36 during mid-day trading on Wednesday, hitting $13.46. The stock had a trading volume of 1,280,000 shares, compared to its average volume of 2,300,000. Intrexon Corp has a twelve month low of $10.26 and a twelve month high of $26.99. The company has a quick ratio of 1.85, a current ratio of 2.05 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $1,700.00, a P/E ratio of -12.02 and a beta of 1.40.
Several hedge funds have recently modified their holdings of XON. Third Security LLC grew its holdings in shares of Intrexon by 2.5% during the fourth quarter. Third Security LLC now owns 57,928,289 shares of the biotechnology company’s stock valued at $667,334,000 after buying an additional 1,423,236 shares in the last quarter. Iridian Asset Management LLC CT grew its stake in Intrexon by 22.5% in the fourth quarter. Iridian Asset Management LLC CT now owns 4,518,112 shares of the biotechnology company’s stock valued at $52,049,000 after purchasing an additional 828,368 shares in the last quarter. First Trust Advisors LP grew its stake in Intrexon by 41.5% in the fourth quarter. First Trust Advisors LP now owns 2,248,411 shares of the biotechnology company’s stock valued at $25,902,000 after purchasing an additional 659,632 shares in the last quarter. Two Sigma Investments LP purchased a new position in Intrexon in the fourth quarter valued at about $2,469,000. Finally, Frontier Capital Management Co. LLC grew its stake in Intrexon by 139.0% in the fourth quarter. Frontier Capital Management Co. LLC now owns 276,284 shares of the biotechnology company’s stock valued at $3,183,000 after purchasing an additional 160,701 shares in the last quarter. Institutional investors and hedge funds own 75.10% of the company’s stock.
XON has been the topic of a number of recent analyst reports. ValuEngine lowered Intrexon from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Zacks Investment Research raised Intrexon from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. Northland Securities reaffirmed a “buy” rating and set a $21.00 target price on shares of Intrexon in a research report on Friday, November 10th. Stifel Nicolaus boosted their target price on Intrexon from $39.00 to $57.00 and gave the stock a “buy” rating in a research report on Friday, November 10th. Finally, Bank of America lowered their price target on Intrexon from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $38.50.
WARNING: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/02/14/intrexon-corp-xon-ceo-randal-j-kirk-acquires-1000000-shares-of-stock.html.
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.